PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-13.58%
Negative revenue growth while RUN stands at 46.33%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-21.95%
Negative gross profit growth while RUN is at 270.34%. Joel Greenblatt would examine cost competitiveness or demand decline.
-32.27%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-195.63%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
167.94%
Net income growth 1.25-1.5x RUN's 141.90%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
168.87%
EPS growth 1.25-1.5x RUN's 133.83%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
155.10%
Diluted EPS growth 1.25-1.5x RUN's 133.83%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
1.77%
Share reduction more than 1.5x RUN's 22.34%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
18.91%
Diluted share count expanding well above RUN's 22.34%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-86.96%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-82.83%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
204.54%
10Y revenue/share CAGR above 1.5x RUN's 14.40%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-29.48%
Negative 5Y CAGR while RUN stands at 14.40%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-43.62%
Negative 3Y CAGR while RUN stands at 14.40%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-246.13%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-122.15%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-319.20%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
113.47%
Net income/share CAGR at 75-90% of RUN's 135.77%. Bill Ackman would press for strategic moves to boost long-term earnings.
174.47%
5Y net income/share CAGR 1.25-1.5x RUN's 135.77%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
106.82%
3Y net income/share CAGR 75-90% of RUN's 135.77%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
No Data
No Data available this quarter, please select a different quarter.
-25.53%
Negative 5Y equity/share growth while RUN is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
16.39%
Equity/share CAGR of 16.39% while RUN is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.43%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
2.59%
Inventory shrinking or stable vs. RUN's 6.64%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
5.98%
Asset growth at 50-75% of RUN's 11.13%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
1.39%
Positive BV/share change while RUN is negative. John Neff sees a clear edge over a competitor losing equity.
-4.55%
We’re deleveraging while RUN stands at 24.76%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-2.87%
Our R&D shrinks while RUN invests at 8.96%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
5.58%
SG&A declining or stable vs. RUN's 18.62%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.